Helio Genomics Reveals Findings on New Colon Cancer Detection Method
Helio Genomics unveiled positive finds of its multimodal epigenetic sequencing assay (MESA) for colon cancer detection.
Read MorePosted by Andy Lundin | Jan 18, 2023 | Colorectal |
Helio Genomics unveiled positive finds of its multimodal epigenetic sequencing assay (MESA) for colon cancer detection.
Read MorePosted by Andy Lundin | Jan 16, 2023 | Company News, Diagnostic Technologies |
LinusBio raised over $16 million to deliver a novel platform that bridges genomics, the environment, and biological response.
Read MorePosted by Andy Lundin | Jan 16, 2023 | Company News, Diagnostic Technologies |
NuraLogix unveiled a platform that performs continuous health and vital sign measurements while on a video telemedicine call.
Read MorePosted by Andy Lundin | Jan 13, 2023 | Disease States |
Twist Bioscience and Centogene N.V. launched three NGS target enrichment panels to support rare disease and hereditary cancer diagnostics.
Read MorePosted by Chris Wolski | Jan 9, 2023 | Molecular Diagnostic Analyzers |
PathogenDx’s involvement with Operation Warp Speed, demonstrated the efficacy of microarray technology for diagnostic testing.
Read More